Drugs / GSK2862277
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01818024 | Feb → Oct 2013 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02221037 | Apr 2015 → Jun 2017 | adult acute respiratory distress syndrome | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2862277 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02221037 ↗ |
| Modality | Protein / enzyme biologic | “modified dAb (GSK2862277)” PMID 26178412 ↗ Sep 2015 |
| Route | Intravenous | “GSK2862277 solution available in a 40 mg vial for IV administration.” NCT01818024 ↗ |